Biobased Market Expansion Act of 2025
The Biobased Market Expansion Act of 2025 would amend the Farm Security and Rural Investment Act of 2002 to strengthen the federal biobased products program. It directs federal procurement policy to expand the use of biobased goods by requiring annual increases in biobased-only contracts or purchase volumes, adding price-preference tools, and clarifying that agencies may exclude products that are either too expensive under the new preference or do not satisfy Buy American Act requirements. The bill also emphasizes products made wholly or partly in the United States and expands the program’s recognition and labeling framework.
The bill further adds implementation and oversight requirements. Federal agencies would need to train contracting staff, update procurement catalogs and data systems to identify eligible biobased products, and improve reporting on compliance, barriers, and unavailable product categories. The Office of Federal Procurement Policy would be required to collect and publicly post agency data and verify agency compliance, while the Government Accountability Office would later review implementation and recommend improvements. The bill also revises USDA reporting to include the economic value returned to agriculture and the geographic distribution of biomanufacturing facilities and biorefineries.
If enacted, the bill would amend 7 U.S.C. 8102, the biobased markets provisions of the Farm Security and Rural Investment Act of 2002, by imposing more explicit federal procurement targets and reporting duties. It would affect federal procuring agencies, the Department of Agriculture, the General Services Administration, and the Office of Federal Procurement Policy by requiring updated guidance, training, catalog changes, public reporting, and compliance verification. The measure is intended to increase federal demand for biobased products and support domestic biomanufacturing and agricultural markets.
The available context shows a generally supportive posture: the bill was introduced by Senators Young and Padilla and referred to the Senate Committee on Agriculture, Nutrition, and Forestry without recorded opposition, amendments, or votes in the provided materials. The text frames the measure as a market-expansion and implementation-improvement bill, suggesting a pro-agriculture, pro-manufacturing, and pro-federal-purchasing-efficiency intent. No committee transcript or vote history is available here to indicate broader debate or resistance.
The main potential points of contention are procurement mandates, price preferences, and compliance burdens. Federal agencies may face added administrative requirements from annual procurement increases, new training obligations, catalog updates, and public reporting. Another likely issue is the balance between promoting biobased products and preserving flexibility for agencies when products are unavailable, too costly, or do not meet Buy American Act standards. Stakeholders favoring domestic biobased manufacturing and agricultural markets would likely support the bill, while procurement officials or agencies concerned about cost, implementation complexity, or supply availability may be more cautious.